Dallas, TX -- (SBWIRE) -- 06/09/2015 -- The report "Post Menopausal Osteoporosis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects.

Complete report on Post Menopausal Osteoporosis with 27 market data tables and 14 figures, spread across 86 pages is available at http://www.rnrmarketresearch.com/post-menopausal-osteoporosis-pipeline-review-h1-2015-market-report.html

Companies discussed in this Post Menopausal Osteoporosis – Pipeline Review, H1 2015 report include Amgen Inc., Chronos Therapeutics Limited, Eli Lilly and Company, Hanmi Pharmaceuticals, Co. Ltd., Merck & Co., Inc., Oncobiologics, Inc, Paras Biopharmaceuticals Finland Oy, Pfizer Inc., Radius Health, Inc., Unigene Laboratories, Inc.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are (aceclofenac + eperisone), abaloparatide, bazedoxifene acetate, blosozumab, calcitonin, denosumab, denosumab biosimilar, Drugs for Postmenopausal Osteoporosis, odanacatib, RDC-5, romosozumab, teriparatide biosimilar.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=388758

(This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report includes:

-Jan 29, 2015: Radius Health Announces Oral Presentation of the ACTIVE Phase 3 Clinical Trial of Abaloparatide-SC for Postmenopausal Women With Osteoporosis at ICE/ENDO 2015

-Dec 21, 2014: Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis

-Nov 24, 2014: The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase II Study of the Investigational Drug Abaloparatide in Postmenopausal Women With Osteoporosis

-Sep 15, 2014: Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia (Denosumab) In Postmenopausal Women With Osteoporosis

-Sep 15, 2014: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis

-Sep 15, 2014: New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density

-Aug 13, 2014: Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director

-Jan 09, 2014: Radius Announces Positive Topline Data From Phase 2 Study of Abaloparatide (BA058) for Postmenopausal Osteoporosis Using Two Delivery Systems

-Jan 02, 2014: Romosozumab phase 2 data published in New England Journal of Medicine show significant increases in bone mineral density at both spine and hip

-Dec 31, 2013: Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip

List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, H1 2015 9
Number of Products under Development for Post Menopausal Osteoporosis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H1 2015 16
Post Menopausal Osteoporosis - Pipeline by Chronos Therapeutics Limited, H1 2015 17
Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H1 2015 18
Post Menopausal Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 19
Post Menopausal Osteoporosis - Pipeline by Merck & Co., Inc., H1 2015 20
Post Menopausal Osteoporosis - Pipeline by Oncobiologics, Inc., H1 2015 21
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015 22
Post Menopausal Osteoporosis - Pipeline by Pfizer Inc., H1 2015 23
Post Menopausal Osteoporosis - Pipeline by Radius Health, Inc., H1 2015 24
Post Menopausal Osteoporosis - Pipeline by Unigene Laboratories, Inc., H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Assessment by Combination Products, H1 2015 27
Number of Products by Stage and Target, H1 2015 29
Number of Products by Stage and Mechanism of Action, H1 2015 31
Number of Products by Stage and Route of Administration, H1 2015 33
Number of Products by Stage and Molecule Type, H1 2015 35
Post Menopausal Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2015 56
Post Menopausal Osteoporosis - Dormant Projects, H1 2015 70
Post Menopausal Osteoporosis - Discontinued Products, H1 2015 71

List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, H1 2015 9
Number of Products under Development for Post Menopausal Osteoporosis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Top 10 Targets, H1 2015 28
Number of Products by Stage and Top 10 Targets, H1 2015 29
Number of Products by Top 10 Mechanism of Actions, H1 2015 30
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 31
Number of Products by Top 10 Routes of Administration, H1 2015 32
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 33
Number of Products by Top 10 Molecule Types, H1 2015 34
Number of Products by Stage and Top 10 Molecule Types, H1 2015 35

Explore more reports on Osteoporosis Drugs at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/osteoporosis-drugs

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.